Paragon 28, Inc. (FNA)

NYSE: FNA · IEX Real-Time Price · USD
17.82
-0.71 (-3.83%)
Sep 30, 2022 4:00 PM EDT - Market closed
-3.83%
Market Cap 1.37B
Revenue (ttm) 162.50M
Net Income (ttm) -29.18M
Shares Out 76.78M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 122,226
Open 18.43
Previous Close 18.53
Day's Range 17.77 - 18.91
52-Week Range 12.35 - 25.41
Beta n/a
Analysts Buy
Price Target 27.34 (+53.4%)
Earnings Date Aug 3, 2022

About FNA

Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to addr... [Read more...]

Industry Medical Devices
IPO Date Oct 15, 2021
Employees 343
Stock Exchange NYSE
Ticker Symbol FNA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for FNA stock is "Buy." The 12-month stock price forecast is 27.34, which is an increase of 53.42% from the latest price.

Price Target
$27.34
(53.42% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Paragon 28 to Present at The Morgan Stanley 20th Annual Global Healthcare Conference

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today that Albert DaCosta, Chairm...

1 month ago - Business Wire

Paragon 28 Announces Changes to its Board of Directors

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced two changes to the composit...

1 month ago - Business Wire

Paragon 28 Reports Second Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial result...

1 month ago - Business Wire

Paragon 28 To Report Second Quarter 2022 Financial Results on August 3, 2022

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financ...

2 months ago - Business Wire

Paragon 28 to Present at The Canaccord Genuity 42nd Annual Growth Conference

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today that Albert DaCosta, Chairm...

2 months ago - Business Wire

Paragon 28 Launches Mobile Medical Education Lab Tour, Expanding Opportunities for Foot and Ankle Surgeon Education

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced its new nationwide mobile t...

2 months ago - Business Wire

Paragon 28 Launches Monkey Rings™ Circular External Fixation System

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the launch of its Monkey Ri...

3 months ago - Business Wire

Paragon 28 Launches TenoTac™ 2.0 Soft Tissue Stabilization System for Hammertoe and Soft Tissue Repair

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced further expansion of its ha...

4 months ago - Business Wire

Paragon 28 Expands Soft Tissue Portfolio with Grappler™ Suture Anchor System Launch

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today an expansion of its soft-ti...

4 months ago - Business Wire

Paragon 28 Reports First Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial result...

4 months ago - Business Wire

Paragon 28 Launches Paratrooper™ Plantar Plate System for Hammertoe and Soft Tissue Repair

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today an expansion of its hammert...

5 months ago - Business Wire

Paragon 28 Launches R3ACT™ Stabilization System for Ankle Injuries

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the launch of its R3ACT™ St...

5 months ago - Business Wire

Paragon 28 To Report First Quarter 2022 Financial Results on May 9, 2022, and Present at the 2022 Bank of America Hea...

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financ...

5 months ago - Business Wire

Can Paragon 28, Inc. (FNA) Climb 63% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 63.3% upside potential for Paragon 28, Inc. (FNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings est...

5 months ago - Zacks Investment Research

Paragon 28 Announces Appointment of Meghan Scanlon to Board of Directors

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the appointment of Meghan S...

6 months ago - Business Wire

Paragon 28, Inc. (FNA) Upgraded to Buy: Here's Why

Paragon 28, Inc. (FNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

6 months ago - Zacks Investment Research

Has Paragon 28, Inc. (FNA) Outpaced Other Medical Stocks This Year?

Here is how Paragon 28, Inc. (FNA) and Gamida Cell (GMDA) have performed compared to their sector so far this year.

6 months ago - Zacks Investment Research

Wall Street Analysts Think Paragon 28, Inc. (FNA) Could Surge 64%: Read This Before Placing a Bet

The consensus price target hints at a 63.7% upside potential for Paragon 28, Inc. (FNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings est...

6 months ago - Zacks Investment Research

Paragon 28 to Present at Upcoming Canaccord Genuity Musculoskeletal Conference and Needham Healthcare Conference

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today that Albert DaCosta, Chairm...

6 months ago - Business Wire

Why Paragon 28 Stock Jumped Today

Investors liked the company's 2022 revenue guidance.

6 months ago - The Motley Fool

Paragon 28 Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Net Revenue Guidance

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported fina...

6 months ago - Business Wire

Paragon 28 to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financ...

7 months ago - Business Wire

Paragon 28 Announces Acquisition of Disior

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the...

8 months ago - Business Wire

Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2021

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a r...

8 months ago - Business Wire

Paragon 28, Inc. R3ACT™ Stabilization System Cleared by FDA

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that the U.S. F...

9 months ago - Business Wire